Vinpocetine enhances cisplatin sensitivity of non-small cell lung cancer cells by reducing the nuclear factor erythroid 2-related factor 2 signaling
Qingyang Zhuang, Yunjian Huang, Yaping Hong, Wu Zhuang, Kai Zhu, Zhangzhou Huang
DOI: 10.1136/jim-2022-002369 Published 17 May 2022
Qingyang Zhuang
1Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China
Yunjian Huang
2Department of Thoracic Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China
Yaping Hong
2Department of Thoracic Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China
Wu Zhuang
2Department of Thoracic Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China
Kai Zhu
2Department of Thoracic Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China
Zhangzhou Huang
2Department of Thoracic Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China
No eLetters have been published for this article.
Vinpocetine enhances cisplatin sensitivity of non-small cell lung cancer cells by reducing the nuclear factor erythroid 2-related factor 2 signaling
Qingyang Zhuang, Yunjian Huang, Yaping Hong, Wu Zhuang, Kai Zhu, Zhangzhou Huang
Journal of Investigative Medicine May 2022, jim-2022-002369; DOI: 10.1136/jim-2022-002369
Vinpocetine enhances cisplatin sensitivity of non-small cell lung cancer cells by reducing the nuclear factor erythroid 2-related factor 2 signaling
Qingyang Zhuang, Yunjian Huang, Yaping Hong, Wu Zhuang, Kai Zhu, Zhangzhou Huang
Journal of Investigative Medicine May 2022, jim-2022-002369; DOI: 10.1136/jim-2022-002369
Vinpocetine enhances cisplatin sensitivity of non-small cell lung cancer cells by reducing the nuclear factor erythroid 2-related factor 2 signaling
Qingyang Zhuang, Yunjian Huang, Yaping Hong, Wu Zhuang, Kai Zhu, Zhangzhou Huang
Journal of Investigative Medicine May 2022, jim-2022-002369; DOI: 10.1136/jim-2022-002369